Our Company
Purpose-driven, Expert-led
Our Mission
Thetis is developing TP-317, a first-in-class, proprietary oral drug based on Resolvin E1 (RvE1), an endogenous lipid that promotes tissue and immune homeostasis. Our targets — ulcerative colitis, Crohn's disease, and cancer — represent significant unmet medical needs.
Our Expertise
Thetis combines pharmaceutical industry leadership with deep expertise in resolution biology to advance the first stable, oral RvE1 therapy into the clinic.
Gary Mathias
Mr. Mathias co-founded Thetis in 2011 and became CEO in 2016, leading the company's development of TP-317 in IBD and cancer. He previously was Managing Director at Carter Morse & Mathias, senior vice president at GE Equity Capital, Chief Operating Officer of Diabetes Support Systems, and executive vice president of Premier Healthcare, a healthcare private equity firm. Mr. Mathias has a bachelor's degree in economics from Harvard College and an MBA from the Yale School of Management. He completed post-graduate work in economic development as a Fulbright Fellow.
Gary Mathias
Co-Founder and CEO
John Parkinson, PhD
Prior to joining Thetis in 2021, Dr. Parkinson was the Senior Scientific Director and Head of IBD Drug Discovery at Takeda Pharmaceuticals, Janssen Pharmaceuticals and Vertex Pharmaceuticals. Earlier in his career, Dr. Parkinson led the discovery and development of the Lipoxin analog program at Berlex Laboratories. Dr. Parkinson completed post-doctoral studies in hematology and oncology at the Indiana University School of Medicine and in cardiovascular drug discovery at the Lilly Laboratories for Clinical Research and received a PhD in biochemistry from the University of Bristol, Bristol, U.K.
John Parkinson, PhD
Chief Science Officer
Joyce Steinberg, MD, FACP
Dr Steinberg is a Board-Certified Medical Oncologist who has over 22 years of biopharma industry experience in drug development. Prior to joining Thetis Pharmaceuticals, Dr. Steinberg held key medical development roles at Searle, Fujisawa, NeoPharm, Abbott, and Astellas specializing in the development of cancer therapies including small molecules and biologics. She has experience in designing, overseeing, and conducting global clinical trials and representing development positions at global regulatory agencies. Dr. Steinberg holds an MD from the Chicago Medical School at Rosalind Franklin University. Her medical oncology fellowship was done at the University of Toronto.
Joyce Steinberg, MD, FACP
Chief Medical Officer
Beverly Paperiello
Ms. Paperiello is a biopharmaceutical executive with over 25 years of experience in the management of clinical development programs and related departments, with responsibility for global clinical research, for large and small molecules and gene therapy, spanning from early stage to late stage development. Her experience includes numerous global development programs and regulatory filings, with portfolio management in excess of ~$1 billion. Ms. Paperiello previously was Senior Vice President, Biopharmaceutical Product Development at Akebia Therapeutics, Head of Clinical Science Oncology at Astellas, Director of Clinical Program Management at Abbott Laboratories, and Manager of Clinical Research at D. Searle/Pharmacia/Pfizer.
Beverly Paperiello
SVP, Development Operations
Robert Lipper, PhD
Dr. Lipper has 30+ years of experience in research and development in the pharmaceutical industry. Prior to his present consulting work, Dr. Lipper held international line-management responsibility for Pharmaceutics R&D with Bristol Myers Squibb over a 24 year career. His experience spans the entire R&D pipeline, from compound selection through technology transfer and marketed product support. Dr. Lipper began his industrial career with Pfizer Central Research, Groton, CT, where he was primarily involved with liquid and sterile product development for human and veterinary pharmaceutical products. Dr. Lipper has a PhD in Pharmaceutical Chemistry from the University of Michigan and B.S. in Pharmacy from Purdue University.
Robert Lipper, PhD
Senior Advisor, Drug Product
Chris Cimarusti, PhD
Dr. Christopher Cimarusti made invaluable contributions to our TP-317 program since he began working with Thetis in 2015. As a discovery chemist during the early part of his career at Squibb Corporation, Dr. Cimarusti synthesized the anti-hypertensive nadolol and the antibiotic aztreonam for the first time and designed their commercial processes. As a discovery leader, he co-led the antibiotic effort with Richard Sykes, and their collaboration produced a landmark 1981 Nature paper — "Monocyclic β-lactam antibiotics produced by bacteria" — that introduced aztreonam to the world and coined the term "monobactam" for this new class of antibiotic. Dr. Cimarusti subsequently became Director of Organic Chemistry for the Squibb Institute for Medical Research and was responsible for all biological and chemical process R&D within Squibb Corporation. After the merger with Bristol-Myers, he became Vice President of Process R&D within the Pharmaceutical Research Institute of Bristol-Myers Squibb. He was appointed Senior Vice President, Pharmaceutical Development and led a global staff of 1,200 engaged in the CMC disciplines for small and large molecules. We mourn his passing while celebrating his remarkable contributions to Thetis and a lifetime of leadership in pharmaceutical drug discovery and development.
Chris Cimarusti, PhD
In Memorium (1943-2026)
Tracy Jennings
Ms. Jennings joined Thetis in 2023 as Senior Director of Clinical Operations with over 20 years of experience in all phases of clinical trials. She has led high-impact studies involving both large and small molecules, as well as gene therapies. Ms. Jennings excels in managing complex clinical programs, navigating the intricacies of global regulatory environments, and driving operational excellence. She previously held clinical operations roles at Intellia Therapeutics and Johnson & Johnson Regenerative Medicine and at several small biotech companies.
Tracy Jennings
Senior Dir., Clinical Operations
Gerald Nabozny, PhD
Dr. Nabozny is an immunologist and inflammation biologist with close to 30 years of experience in pharmaceutical R&D. Prior to joining Thetis, he was a Highly Distinguished Research Fellow in the Department of Immunology and Respiratory Diseases Research at Boehringer Ingelheim Pharmaceuticals. As a member of the department's executive leadership team, Dr. Nabozny played a central role in the discovery, development and approval of Skyrizi and Spevigo, and served as research lead for the clinical development of Skyrizi across psoriasis, psoriatic arthritis, and inflammatory bowel disease. He established and led a group focused on disease positioning and early biomarker discovery, developing target engagement, pharmacodynamic and disease-associated biomarker strategies for transfer into clinical trials. He completed a Research Fellowship in the Department of Immunology at the Mayo Clinic and Medical School and holds a Ph.D. in immunology.
Gerald Nabozny, PhD
Director, Biomarker Strategy
Leadership
David C. Jordan, PhD
Dr. David Jordan received his MS and PhD in statistics from the University of Kentucky and has 35+ years of experience in the pharma industry with Mead Johnson, Searle, Pharmacia, Pfizer and Abbott. Since retiring from Abbott in 2012 as Divisional VP, Statistics and Data Management, Dr. Jordan has engaged in statistical consulting for the biopharma industry.
David's professional experience includes directing the statistical contributions for dozens of NDAs/BLAs, MAAs, sNDAs/sBLAs for compounds across numerous therapeutic areas. His areas of expertise include biostatistics, clinical trial design and the conduct and evaluation of clinical trials.
Dave Jordan, PhD
Director, Biostatistics
Belinda Hightower, RN, PhD
Dr. Hightower joined Thetis in 2023 with nearly forty years of pharmaceutical industry experience as an expert in clinical quality management. She has held leadership roles in quality management and made significant contributions towards the development and marketing of several drugs and has held positions with Abbott Laboratories (AbbVie), Upjohn and GH Besselaar. Dr. Hightower is a Registered Nurse and holds a dual Doctorate and Masters in International Business from the Keller Graduate School of Management and a Bachelor's of Science degree from DePaul University.
Belinda Hightower, RN, PhD
VP, Clinical Quality Management
Tracy Lessor, PhD, MBA, ELS
Tracy Lessor is a seasoned science and corporate communications professional specializing in the biotech and pharmaceutical industries, with more than 25 years of experience in corporate and agency settings. Tracy previously was Executive Director of Corporate Affairs and Investor Relations at Schrödinger, where she led all external and internal communications. At Amgen, she directed communications for the biosimilars division including the global launch of Amgen’s initial five biosimilar medicines. At Feinstein Kean Healthcare/Ogilvy, Tracy was senior vice president of science communications for more than a decade. She earned a Ph.D. in molecular and cell biology at the University of Medicine Greenebaum Cancer Center, an M.B.A. at Babson College, and is a board-certified Editor of the Life Sciences (ELS).
Tracy Lessor, PhD, MBA
Director, Communications
Fabio Cataldi, MD
Dr. Cataldi joined Thetis as an independent board member in July 2024 and currently serves as chief medical officer (CMO) of Abivax SA. Prior to Abivax, he was CMO at Landos Biopharma through its sale to AbbVie in 2024. He brings deep clinical, medical, and scientific knowledge and expertise in immunology and gastroenterology, having served in senior research and development roles at Arena Pharmaceuticals, AbbVie, Shire, Pfizer, Biogen, and Novartis. He received his medical degree from the Second University V Division of General Surgery in Naples, Italy, and completed post-doctoral research at Beth Israel Deaconess Medical Center in Boston.
Fabio Cataldi, MD
Independent Board Member
David N. Cook, PhD
Dr. Cook is a veteran biotech executive with more than three decades of leadership in clinical development, scientific strategy, and corporate growth. He currently is the CEO of Edgewood Oncology and has served as CEO or CSO at several companies, including Forma Therapeutics, Seres Therapeutics, Anza Therapeutics, Eligix, and Cerus Corporation. Over the course of his career, he has helped raise more than $1 billion through IPOs, follow-on financings, partnerships, and non-dilutive funding, and played a central role in multiple corporate acquisitions. Dr. Cook has contributed to the development and commercialization of five licensed products. He earned his A.B. in American studies from Harvard University and his Ph.D. in chemistry from the University of California, Berkeley.
David N. Cook, PhD
Independent Board Member
Gary Mathias
Mr. Mathias co-founded Thetis in 2011 and became CEO in 2016, leading the company's development of TP-317 in IBD and cancer. He previously was Managing Director at Carter Morse & Mathias, senior vice president at GE Equity Capital, Chief Operating Officer of Diabetes Support Systems, and executive vice president of Premier Healthcare, a healthcare private equity firm. Mr. Mathias has a bachelor's degree in economics from Harvard College and an MBA from the Yale School of Management. He completed post-graduate work in economic development as a Fulbright Fellow.
Board of Managers
Gary Mathias
Co-Founder and CEO
Walter Ogier
Mr. Ogier has been an advisor to Thetis since 2012 and joined the board in 2016. He has more than 30 years of experience developing therapeutic medical products ranging from pharmaceuticals to medical devices, stem and immune cell therapies and gene therapies. He has served in multiple CEO roles including Genetix Pharmaceuticals, Inc. (now bluebird bio, Inc.) and Acetylon Pharmaceuticals, Inc., which Celgene Corporation acquired in 2016. He also was a director of Eledon Pharmaceuticals Inc. (NASDAQ: ELDN), Biothera Pharmaceuticals, Inc., and Nemucore Medical Innovations, Inc., and a Board advisor to Kodikaz Therapeutic Solutions, Inc. and ME Therapeutics, Inc. Mr. Ogier earned a Master of Business Administration from Yale School of Management and a Bachelor of Arts in Chemistry from Williams College.
Walter Ogier
Independent Board Member
Frank C. Sciavolino, PhD
Dr. Sciavolino has extensive experience in the pharmaceutical industry, including a distinguished 35 year career at Pfizer Global R&D. At Pfizer, Dr. Sciavolino held various management roles and responsibilities in drug discovery, development, registration and licensing, culminating in a role as Vice President of R&D Operations, in which he oversaw a team of 1,000 scientists in the United States, Europe and Asia. He was the enabling force behind two of Pfizer's most notable franchises, Zithromax and Celebrex. After leading the discovery chemistry team responsible for the initial macrolide antibiotic research, he served as principal investigator leading the Phase I evaluation of 11 compounds in first-in-human (FIH) studies, which led to the identification and development of Zithromax, an antibiotic considered one of the most important new drugs of the 20th century. He also played a major role in the licensing of Celebrex, a COX-2 inhibitor that reached $3 billion in peak annual sales globally.
Dr. Sciavolino has served on numerous editorial boards including Annual Reports in Medicinal Chemistry, Antimicrobial Agents and Chemotherapy and the Journal of Antibiotics. Dr. Sciavolino has more than 30 issued patents and has a Ph.D. in organic chemistry from the University of Michigan and B.S. in Pharmacy from St. John's University.
Frank C. Sciavolino, PhD
Co-Founder and CSO Emeritus
Dennis Willson, JD
Mr. Willson has been a board member of Thetis since 2012. He previously was President & CEO of ITF Pharma, Inc. and co-founder and chairman of Hsiri Therapeutics, LLC, a start-up company focused on the development of new antibiotics for drug-resistant infections. Prior to his time at ITF, he was co-founder, President & CEO of Cytokine PharmaSciences, Inc., a biopharmaceutical company focused on women's health, inflammation and cancer. Mr. Willson spent 19 years in leadership positions at Cytokine, managing the successful development and licensing of several products, including Cervidil, one of the world's leading obstetric products. In October 2011, he led the company in a strategic sale to Ferring S.A.
Before joining Cytokine, Mr. Willson held management, finance and business development positions at Abbott Laboratories, Rorer International, and Carrington Laboratories. Mr. Willson graduated summa cum laude from the University of Notre Dame with a degree in psychology and modern languages and has a law degree from the University of California, Hastings College of the Law.
Dennis Willson
Independent Board Member
|
Silvio Danese, MD, PhD
San Raffaele University and Hospital
Stephen Hanauer, MD
Northwestern Medicine
Jeffrey Hyams, MD
Connecticut Children's Hospital
Joshua Korzenik, MD
Brigham & Women's Hospital
|
Laurent Peyrin-Biroulet, MD, PhD
Nancy University Hospital
Walter Reinisch, MD
Medical University of Vienna
Bruce Sands, MD
Icahn School of Medicine, Mount Sinai
Bram Verstockt, MD, PhD
University Hospitals Leuven
|
|
Wayne Klohs, PhD
Former Global Head, Astellas Oncology
Manuel Hidalgo, MD, PhD
NYU Langone / Perlmutter Cancer Center
Sui Huang, MD, PhD
Institute for Systems Biology
Eileen O'Reilly, MD
Memorial Sloan Kettering Cancer Center
|
David Parkinson, MD
ESSA Pharma
Erin Schenk, MD
Univ. of Colorado School of Medicine
Mario Sznol, MD, Emeritus
Yale School of Medicine
Chris Takimoto, MD, PhD, FACP
START Center for Cancer Research
|
Funding From Leading Philanthropies
Backed by $20M+ from institutions committed to advancing resolution therapy
